Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WU-CART-007 in Relapsed/Refractory T-ALL/LBL (T-RRex)
NCT06514794Phase 2Recruiting
- Sponsor
- Wugen
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of soficabtagene geleucel in t-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LL), sponsored by Wugen. Primary endpoints: Composite Complete Response Rate at 24 months and Response Rate at 24 months. Started Jan 2025; status: recruiting.
02
Drugs
soficabtagene geleucel
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT06514794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06514794.